The Opportunity
Imagine a future where orthopedic surgeons no longer hack off bone ends and jam in metal-and-plastic implants—a relic from the 1950s that’s overdue for disruption. It’s coming. Preservation technologies is on the rise, poised to heal cartilage, regrow bone, and sideline invasive joint replacements, yet innovative startups remain scattered and outgunned by Big Ortho giants fiercely protecting their billion-dollar joint replacement empire.
The Problem Today
Many patients in the US are coached by the system to get a a premature joint replacement. Often, the best joint preservation products are not discussed with the patient. There are extraneous factors driving this incumbency. The total joint ortho companies that control most of the financial resources and control most of the product access into hospitals and ASCs, do not want to upset the golden goose – total joint replacements. The preservation ortho companies have fewer resources and little control over product access in the healthcare systems and are challenged to get traction in the marketplace.
The Big Question
As you know, I’m always scouting the edges of the startup orthopedic world. Lately, I’ve been trying to steel man an idea that’s popped up in a few BoneChat discussions with Alyssa Huffman, Brad Estes, Patrick Jamnik and other startup leaders that asked:
What if we rolled up a bunch of these preservation properties into one powerhouse entity?
Enter JointSave
Enter our bold thought experiment: What if we rolled up these pioneers into the “JointSave Consortium,” a powerhouse merging IP, resources, and market muscle to end the 20-year agony for 40-65-year-olds stuck between painkillers and scalpels?
JointSave is inspired by H.I.G. Capital’s recent spine roll-up (ZimVie) named Highridge Medical and Montagu Private Equity recent CDMO roll-up named Tyber Medical + Intech + Resolve Surgical Technologies.
This isn’t just blue-sky thinking. The regenerative space is fragmented, with tons of promising companies tackling joint preservation, cartilage regeneration, bone healing, and delay tactics for total joint replacements. But they’re all fighting the same battles: funding droughts because they’re “creating the market,” regulatory hurdles, and the shadow of big players like ZB or Stryker who might swoop in to buy and bury (or, optimistically, integrate). A roll-up could flip the script – pool IP, diversify pipelines from Class I devices to PMAs, and create a billion-dollar exit magnet for private equity (PE) or strategics.Inspired by spine roll-ups like those from Highridge Medical (spine consortium) or even broader medtech consolidations, let’s game this out.
Imagine a PE firm steps in, acquires 5 to 10 complementary startups, and builds the “JointSave Consortium.” focused on patients aged 40-65 – that miserable cohort stuck with HA injections, painkillers, and braces while waiting for totals. The goal? Delay or avoid replacements altogether, blending medtech with regenerative biology. Medtech needs regen, as one founder put it, to compete with biologics and capture that elusive market.
Why Now?
Potential downsides? Integration headaches, culture clashes, and if a strategic buys it… well, shelf it or scale it?
But the upside is a paradigm shift: A company that “gives way to biologic tissue over time,” re-educating surgeons and payers on non-replacement ortho.
1/ Huge Unmet Need for Patients
Between conservative care and totals, there’s a 20-year gap of suffering for early OA patients. Regenerative options like stem cells, scaffolds, and bioabsorbables could regenerate cartilage, heal menisci, or stabilize joints without burning cutting away good bone, burning bridges and bringing revision eventuality into the patients lifetime.
2/ Preservation vs. Big Ortho
Big Orthos don’t love delaying their bread-and-butter totals. In fact, I believe that they will stiff arm preservation solutions if these treatments delay total hips and knees and other joints. Also the profit is in joint replacement, not cells. Look at the revenue math – centrifuge systems net peanuts ($50-100 profit), while a joint replacement could command premiums.
3/ Funding & Exit Challenges
Many of these preservation companies are bootstrapping or scraping Series A/B. Others are zombie public companies like Anika and Bioventus. A roll-up de-risks by combining data, sales channels, and even direct-to-consumer plays.
4/ PE Playbook
PEs can fund the bundle, prove synergies, sell to a strategic for multi-billions. Early, mid, and late-stage assets mean staggered revenue – some 510(k)s flowing cash now, PMAs building value.
Proposing the Roll-Up: Some Targets to Bundle
Here’s a hypothetical basket of egenerative ortho companies at different stages. I picked these based on their focus on bone/cartilage regen, joint preservation, and complementary tech (e.g., scaffolds, stem cells, bioabsorbables). They’re at various stages, from seed to commercial, for a balanced portfolio. (Note: This is speculative – no inside deals here, just scouting vibes.)
Anika Therapeutics
- HQ/Founded: US, 1992
- Core Tech & Focus: Joint preservation solutions including hyaluronic acid injections and regenerative implants for osteoarthritis and cartilage repair.
- Public (NASDAQ: ANIK); Market cap ~$150M.
- Why It Fits the Roll-Up: Adds non-invasive and regenerative options like HA injections for the 40-65 age group, bridging conservative care and surgery.
BioVentus
- HQ/Founded: Durham, NC, USA, 2012
- Core Tech & Focus: Innovations for active healing, including pain treatments and joint preservation (e.g., for osteoarthritis and chronic pain management via peripheral nerve stimulation), restorative therapies for minimally invasive fracture treatments and bone healing, and surgical solutions like bone graft substitutes and ultrasonic technologies for tissue removal and regeneration.
- Public (NASDAQ: BVS); Market cap ~$538M. Went public in 2021; Recent Q1 2025 results showed revenue of $123.9M with 5% organic growth, and reaffirmed 2025 revenue guidance of ~$565M.
OSSIO
- HQ/Founded: Woburn, MA, USA (with R&D in Caesarea, Israel), 2014
- Core Tech & Focus: Bio-integrative orthopedic fixation implants using OSSIO fiber® technology, a proprietary material stronger than cortical bone that provides stable fixation during healing before fully integrating into native bone without leaving permanent hardware; focused on transforming bone healing in foot/ankle, hand/wrist, and other orthopedic applications.
- Stage/Funding Highlights: Private; Raised $88M+ across rounds, including $27.6M in 2024 equity funding.
- Why It Fits the Roll-Up: Offers metal-free, bioabsorbable alternatives for fracture and joint fixation, complementing preservation strategies by enabling natural regeneration and reducing complications from traditional hardware
Subchondral Solutions
- HQ/Founded: Costa Mesa, CA, USA, 2013
- Core Tech & Focus: Developer of orthopedic implants for repairing subchondral bone damage and osteochondral defects, featuring the S-Core® platform—a hydroxyapatite-coated titanium implant that provides biomechanical support, allows nutrient flow through fenestrations, and restores joint function in areas like knees, ankles, shoulders, elbows, and feet.
- Stage/Funding Highlights: Private; Raised Series C in 2022 (amount undisclosed, led by Axxcess Capital Partners); FDA cleared in 2019.
- Why It Fits the Roll-Up: Addresses subchondral bone insufficiency to prevent cartilage degradation and delay end-stage osteoarthritis, adding a structural fixation component to joint preservation strategies without invasive hardware.
Just Bone Orthopedic Solutions
- HQ/Founded: Scottsdale, AZ, USA, 2024
- Core Tech & Focus: Distribution of precision-engineered orthopedic devices for bone and joint regeneration, with a focus on the AlloMate Bone Pin System—an allograft cortical bone pin system that provides fixation for fractures, osteotomies, and joint fusions, fully integrating into the patient’s bone to augment natural healing without leaving permanent hardware.
- Stage/Funding Highlights: Private; Early-stage with 2-10 employees; Funding undisclosed.
- Why It Fits the Roll-Up: Adds bio-integrative, resorbable fixation options using human allograft materials, complementing regenerative strategies by enabling natural bone incorporation and reducing long-term complications in joint preservation and reconstruction.
ExplantLab
- HQ/Founded: Newcastle Upon Tyne, UK, 2011
- Core Tech & Focus: Independent orthogenomics research organization developing Orthotype, a patented genetic test using next-generation DNA sequencing to predict patient-specific risk of implant failure; also specializes in explant analysis with peer-reviewed methodologies to enhance orthopedic implant design, manufacturing, and performance for better patient outcomes.
- Stage/Funding Highlights: Private; Raised $320K in grant funding from Innovate UK.
- Why It Fits the Roll-Up: Provides predictive genetic tools to minimize implant failures and revision surgeries, supporting joint preservation by enabling personalized, less invasive orthopedic care and aligning with regenerative approaches to extend natural joint lifespan.
CytexOrtho
- HQ/Founded: US, 2013
- Core Tech & Focus: Biodegradable implants for cartilage regeneration in hips and knees, using 3D weaving technology.
- Stage/Funding Highlights: FDA approval for trials in 2024; Raised ~$10M.
- Why It Fits the Roll-Up: Focuses on one-stage cartilage restoration, delaying joint replacements. 2 sources
Nanochon
- HQ/Founded: US, 2016
- Core Tech & Focus: 3D-printed scaffolds for cartilage repair, promoting natural tissue regrowth.
- Stage/Funding Highlights: Seed stage; Raised $4M in 2023.
- Why It Fits the Roll-Up: Targets early-stage joint degeneration with minimally invasive implants.
Hyalex Orthopaedics
- HQ/Founded: US, 2017
- Core Tech & Focus: Synthetic cartilage implants mimicking natural properties for joint preservation.
- Stage/Funding Highlights: Series A; Raised $16M.
- Why It Fits the Roll-Up: Provides cartilage replacement without full joint surgery, ideal for younger patients.
Icarus Medical
- HQ/Founded: Charlottesville, VA, USA, 2019
- Core Tech & Focus: Developer of custom knee braces using a proprietary 3D scanning app for at-home or in-office fitting, combined with additive manufacturing and biomechanics to create lightweight, adjustable unloaders that reduce joint load, alleviate pain, and improve mobility for patients with osteoarthritis, meniscus issues, and post-op recovery; products include the Ascender (tricompartment unloader), Adonis (joint distraction for medial/lateral OA and meniscus protection), Hercules (extension-assist KAFO), Hermes (dorsi-assist AFO), and Kronos (post-op brace).
- Stage/Funding Highlights: Private; Raised $4.59M total, including grants like $600K from Virginia Catalyst in 2021 and $20K in 2020, with investors such as Lighthouse Labs, 434, and Commonwealth Research Commercialization Fund; accelerator/incubator backed.
- Why It Fits the Roll-Up: Offers non-invasive, patient-specific bracing for knee preservation and OA management, bridging conservative care with regenerative approaches by offloading joints to delay surgery and reduce complications from invasive procedures.
Cytonics Corporation
- HQ/Founded: Jupiter, FL, USA, 2006
- Core Tech & Focus: Biotechnology company specializing in protease inhibitor therapies for osteoarthritis, featuring the APIC system—an autologous platelet-integrated concentrate that isolates Alpha-2-Macroglobulin (A2M) from blood to inhibit cartilage-degrading enzymes—and CYT-108, a recombinant “super A2M” designed to provide disease-modifying treatment by blocking inflammation and promoting joint health.
- Stage/Funding Highlights: Private; Raised over $25M total ($15M from equity crowdfunding); FDA-approved APIC as a medical device; Currently in Phase 1 clinical trials for CYT-108, seeking $24M for Phase 2 as of March 2025.
- Why It Fits the Roll-Up: Delivers molecular-level interventions to halt OA progression and preserve cartilage without surgery, aligning with regenerative strategies to delay joint replacements and adding a biologic therapy arm to challenge Big Ortho’s replacement-focused model.
Sparta Biomedical
- HQ/Founded: US, 2018
- Core Tech & Focus: Implant technology for knee osteoarthritis, restoring movement and preserving joints.
- Stage/Funding Highlights: Early stage; Funding undisclosed.
- Why It Fits the Roll-Up: Advances in orthopedic implants focused on joint restoration. 2 sources
MiMedx Group
- HQ/Founded: US, 2006
- Core Tech & Focus: Allograft-based regenerative products for wound healing and musculoskeletal applications.
- Public (NASDAQ: MDXG); Market cap ~$1B.
- Why It Fits the Roll-Up: Orthobiologics for tissue regeneration, complementing bone and cartilage repair. 2 sources
Vericel Corporation
- HQ/Founded: US, 1989
- Core Tech & Focus: Autologous cell therapies for cartilage repair and burns, including MACI for knee defects.
- Stage/Funding Highlights: Public (NASDAQ: VCEL); Market cap ~$2B.
- Why It Fits the Roll-Up: Leader in regenerative biologics for orthopedic conditions like OA.
Jointechlabs
- HQ/Founded: US, 2015
- Core Tech & Focus: Point-of-care regenerative therapies using microfat for joint injections.
- Stage/Funding Highlights: Private; Raised ~$5M.
- Why It Fits the Roll-Up: Adds stem cell and orthobiologic arm for non-surgical treatments.
GreenBone Ortho
- HQ/Founded: Italy, 2014
- Core Tech & Focus: Bone regeneration therapy using biomimetic scaffolds for defects.
- Stage/Funding Highlights: Series B; Raised €8M.
- Why It Fits the Roll-Up: Complements bone healing in joint preservation.
NUSurface (fka Active Implants)
- HQ/Founded: US, 2004
- Core Tech & Focus: NUsurface meniscus implant for knee preservation.
- Stage/Funding Highlights: Private; Raised $40M+.
- Why It Fits the Roll-Up: Delays knee replacements with meniscus regeneration.
Sarcio
- HQ/Founded: US, 2020
- Core Tech & Focus: Cartilage restoration solutions using regenerative medicine.
- Stage/Funding Highlights: Early stage; Funding undisclosed.
- Why It Fits the Roll-Up: Targets cartilage defects with biologic approaches.
InGeneron
- HQ/Founded: US, 2006
- Core Tech & Focus: Cell-based therapies for orthopedic regeneration using adipose-derived cells.
- Stage/Funding Highlights: Private; Raised $50M+.
- Why It Fits the Roll-Up: Point-of-care stem cell therapies for tissue healing.
BioPoly
- HQ/Founded: US, 2008
- Core Tech & Focus: Partial resurfacing implants for knee and shoulder preservation.
- Stage/Funding Highlights: Private; Funding undisclosed.
- Why It Fits the Roll-Up: Hybrid material for cartilage repair.
EpiSurf
- HQ/Founded: Sweden, 2009
- Core Tech & Focus: Personalized implants and surgical tools using 3D imaging for treating focal cartilage and osteochondral defects in knees.
- Stage/Funding Highlights: Public (Nasdaq Stockholm)
- Why It Fits the Roll-Up: Enhances joint preservation with minimally invasive, patient-specific solutions for early cartilage damage.
NewClip
- HQ/Founded: France, 2002
- Core Tech & Focus: Osteosynthesis implants and instruments for trauma and elective surgery, focusing on fixation systems for upper limb (clavicle, shoulder, elbow, wrist, hand), lower limb (hip, knee), and foot & ankle.
- Stage/Funding Highlights: Private; Funding undisclosed.Why It Fits the Roll-Up: Adds innovative fixation technologies like polyaxial locking for joint trauma repair and preservation.
BodyCad
- HQ/Founded: Quebec City, Canada, 2011
- Core Tech & Focus: Proprietary Personalized Restoration Software for creating patient-specific orthopedic implants and surgical guides, focusing on customized solutions for osteotomy, oncology, and joint restorations based on individual anatomy.
- Stage/Funding Highlights: Private; Funding undisclosed.
- Why It Fits the Roll-Up: Enhances joint preservation with personalized, 3D-modeled implants and tools that address specific cartilage and bone defects minimally invasively.
Ermi
- HQ/Founded: US, 1991
- Core Tech & Focus: Devices for joint contracture treatment and preservation.
- Stage/Funding Highlights: Private; Acquired in 2023.
- Why It Fits the Roll-Up: Non-invasive options for joint mobility.
FX Shoulder USA
- HQ/Founded: US, 2014
- Core Tech & Focus: Shoulder preservation implants and prosthetics.
- Stage/Funding Highlights: Private; Funding undisclosed.
- Why It Fits the Roll-Up: Focus on joint realignment in shoulders.
Intellirod Spine
- HQ/Founded: US, 2003
- Core Tech & Focus: Sensors for spinal fusion monitoring, aiding preservation.
- Stage/Funding Highlights: Private; Raised $10M+.
- Why It Fits the Roll-Up: Tech for bone healing and stabilization.
REGENECURE
- HQ/Founded: Israel, 2009
- Core Tech & Focus: Biomaterials for bone tissue engineering and joint preservation.
- Stage/Funding Highlights: Private; Funding undisclosed.
- Why It Fits the Roll-Up: Membranes for guided bone regeneration.
This rollup mix covers spine, extremities, joints, and biologics – not all PMAs, with some 510(k)s and even Class I for quick wins.
Total hypothetical valuation?
Start at $500M-$1B acquisition cost, scale to $5B+ exit with synergies.
How to Pull It Off: Step-by-Step
- PE Lead: A firm like KKR or Carlyle scouts and funds the initial 5-7 acquisitions, using a platform company (e.g., Bioventus as anchor if private).
- Synergies: Shared R&D for hybrid implants (e.g., Ossio’s fixation + EpiBone’s grafts); combined clinical data to “re-educate” academics/hospitals; DTC marketing like Bear Implant to build demand.
- Sales Strategy: Avoid building a massive sales force – leverage DTC, ASC partnerships, and regen clinics. As data piles up (e.g., cartilage regrowth proof), payers follow.
- Exit Horizon: 5 years to multi-billion sale. Strategics buy to own preservation therapies without losing totals; or go public as the “JointSave.”
- Risks & Twists: Regulatory alignment? IP overlaps? But if it works, it’s a game-changer – no more “miserable for 20 years.”
What do you think, Ortho folks ?
Hit me up if you’re a founder in this space – we chat offline.
And if a PE reader wants to make it real… my email works – tiger@tigerbuford.com